We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
News

Shasun Pharmaceuticals and Debiopharm Enter Into Licensing Agreement

Rectangle Image
News

Shasun Pharmaceuticals and Debiopharm Enter Into Licensing Agreement

Read time:
 

Shasun Pharmaceuticals Ltd and Debiopharm Group™ (Debiopharm) have entered into a licensing agreement for the manufacturing and commercialization of Huperzine-A.

Huperzine-A is a potent and reversible acetylcholinesterase inhibitor and clinical studies have shown a significant improvement in memory deficit and cognitive performance in patients with Alzheimer’s disease. Huperzine-A is commercially available through Shasun Pharmaceuticals.

According to the terms of the agreement, Shasun Pharmaceuticals Ltd will be able to use the Debiopharm technology for the manufacture of synthetic Huperzine-A under GMP quality conditions and commercialize it in pharmaceutical and nutraceutical markets.

The manufacturing technology involves a 10-stage chemical synthesis process including a complex chiral organometallic step as a key transformation of the Huperzine-A structure.

The synthesis is a result of a joint collaboration between Shasun’s research centers in Chennai and the UK.

This technology was recently recognized and awarded at the North East of England Process Industry Cluster (NEPIC), Innovation Awards in 2012.

NEPIC is a stand-alone company created to represent the 500+ Pharmaceutical, Biotechnology, Specialty Chemical, Polymer & Rubber, Petrochemical & Commodity Chemical companies based in the North East of England.

Commenting on the agreement, Dr Mauvernay, President and founder of Debiopharm Group™ said, “We are delighted to continue our collaboration with Shasun Pharmaceuticals Ltd. Clinical studies have demonstrated the drug to enable significant improvement in both memory deficit and cognitive performance and we are excited to have the opportunity to add value to this technology while contributing to improve people’s quality of life.”

Dr Michel Spagnol, President of Shasun Pharmaceuticals Ltd added, “We are very proud of this achievement, resulting from a very close collaboration with Debiopharm. It underlines our commitment to delivering cutting-edge science in all our processes through our global research and development network.”

Advertisement